Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

Yong Luo, Xiaobing Yang, Spyridon P. Basourakos, Xuemei Zuo, Dechao Wei, Jiahui Zhao, Mingchuan Li, Qiankun Li, Tao Feng, Pengju Guo, Yongguang JiangFrontiers in Molecular Biosciences 2021 · DOI

Abstract

Previous studies showed that CXCR7 expression was upregulated after enzalutamide (ENZ) treatment, and an increased level of CXCR7 could increase the invasion, migration, and angiogenesis of castration-resistant prostate cancer (CRPC) cells. This study demonstrated that the levels of p-JAK2, p-STAT1, C-Myc, and VEGFR2 were significantly reduced after CCX771, a specific CXCR7 inhibitor, treatment. This effect further increased after the combination treatment of ENZ and CCX771. Then, we verified that targeting the inhibition of JAK2 or STAT1 could remarkably increase apoptosis and DNA damage and decrease the migration of CRPC cells. More importantly, the combination treatment of ENZ + JAK2/STAT1 led to much greater suppression than the single-agent treatment of JAK2 or STAT1. Subcutaneous CRPC xenograft tumor growth was also reduced by single-agent ENZ treatment and single-agent FLUD, a specific STAT1 antagonist, treatment; but much superior effect was elicited by the combination treatment of ENZ + FLUD. The proliferative indices significantly decreased following combination treatment in tumor tissues compared with control-treatment tissues and single-agent-treatment tissues. Our results demonstrated that CXCR7, which signifies an androgen receptor (AR)-independent signaling pathway, caused CRPC progression via the downstream JAK2/STAT1 signal transduction cascade. Combined inhibition targeting both the AR and JAK2/STAT1 resulted in substantial tumor suppression due to the reduction in DNA damage repair ability and increment in apoptosis.

Introduction

Castration-resistant prostate cancer (CRPC) is an advanced and aggressive stage of malignancy that has evolved to bypass traditional hormone therapies. While second-generation androgen receptor (AR) antagonists like enzalutamide (ENZ) were developed to block the hormones fueling these tumors, clinical resistance remains a significant barrier. Approximately 42% of patients fail to respond to ENZ, and those who do often develop resistance within a year.

This study investigates the molecular mechanisms driving this resistance. Previous research indicated that the protein CXCR7 becomes overactive when the AR is suppressed. This paper identifies the specific downstream machinery—the JAK2/STAT1 signaling cascade—that CXCR7 utilizes to drive cancer progression and bypass AR inhibition.

Methods and Materials

The research team employed a multi-pronged approach to map the signaling cascade:

  • Cellular Models: Human C4-2B cells were used to model the human prostate cancer line in an androgen-independent state.
  • Pharmacological Inhibition: Specific inhibitors were used to block pathway components: CCX771 (CXCR7), AZD1480 (JAK2), and Fludarabine (STAT1).
  • Genetic Silencing: siRNA transfection was utilized to "knock down" JAK2 and STAT1 genes to verify their specific roles.
  • Functional Assays: Protein expression was measured via Western blotting, while cellular impacts were assessed through migration assays, flow cytometry for apoptosis, and DNA fragmentation analysis.
  • In Vivo Validation: Subcutaneous xenograft tumors were established in castrated SCID mice to test the efficacy of combination therapy (ENZ + Fludarabine) in a living system.

Results

CXCR7 Drives Resistance via the JAK2/STAT1 Cascade

When ENZ blocks the androgen receptor, the cell compensates by "derepressing" or turning on CXCR7. The study identifies the JAK2/STAT1 signaling cascade as the primary engine CXCR7 uses to maintain tumor growth. Treatment with the CXCR7 inhibitor CCX771 significantly reduced the levels of phosphorylated (active) JAK2 and STAT1, as well as downstream oncogenic markers like C-Myc and VEGFR.

CXCR7 inhibition reduces JAK2/STAT1 signaling and downstream oncogenic markers.

The combination of ENZ and CCX771 resulted in a more pronounced suppression of these markers than single-agent treatments, highlighting the synergy between blocking the AR and the CXCR7-driven bypass pathway.

Impairing DNA Repair and Inducing Apoptosis

A major finding of the study was that the JAK2/STAT1 pathway is vital for DNA repair in CRPC cells. Inhibiting JAK2, either through genetic silencing (siRNA) or pharmacological blockade (AZD1480), significantly reduced the expression of DNA-PKcs, a protein essential for repairing double-strand DNA breaks.

JAK2 inhibition downregulates DNA repair proteins and promotes apoptosis.

This reduction in repair capacity makes cancer cells more fragile. The inhibition led to increased DNA damage (indicated by rH2AX) and a significant shift toward programmed cell death (apoptosis), marked by increased cleaved PARP-1 and decreased Bcl-2 levels. In animal models, the combination of ENZ and the STAT1 antagonist Fludarabine was vastly superior to either drug alone, significantly reducing tumor volume and cellular proliferation indices (Ki67).

Discussion and Future Directions

This research highlights the "anomalous" role of STAT1 in CRPC as a pro-survival factor rather than its typical role in anti-tumor immunity. By identifying the CXCR7/JAK2/STAT1 axis as a key resistance mechanism, the study provides a strong rationale for "pincer movement" therapies that target both the AR and this bypass signaling pathway.

However, limitations exist. The study primarily utilized the C4-2B cell line; given the heterogeneity of prostate cancer, results may vary across different patient-derived models. Furthermore, while Fludarabine served as a proof-of-concept, its systemic toxicity suggests a need for more targeted, low-toxicity JAK2 or STAT1 inhibitors for future clinical applications. Future work will focus on mapping the cross-talk between this pathway and other known resistance mechanisms.

Summary updated

Abstract

Previous studies showed that CXCR7 expression was upregulated after enzalutamide (ENZ) treatment, and an increased level of CXCR7 could increase the invasion, migration, and angiogenesis of castration-resistant prostate cancer (CRPC) cells. This study demonstrated that the levels of p-JAK2, p-STAT1, C-Myc, and VEGFR2 were significantly reduced after CCX771, a specific CXCR7 inhibitor, treatment. This effect further increased after the combination treatment of ENZ and CCX771. Then, we verified that targeting the inhibition of JAK2 or STAT1 could remarkably increase apoptosis and DNA damage and decrease the migration of CRPC cells. More importantly, the combination treatment of ENZ + JAK2/STAT1 led to much greater suppression than the single-agent treatment of JAK2 or STAT1. Subcutaneous CRPC xenograft tumor growth was also reduced by single-agent ENZ treatment and single-agent FLUD, a specific STAT1 antagonist, treatment; but much superior effect was elicited by the combination treatment of ENZ + FLUD. The proliferative indices significantly decreased following combination treatment in tumor tissues compared with control-treatment tissues and single-agent-treatment tissues. Our results demonstrated that CXCR7, which signifies an androgen receptor (AR)-independent signaling pathway, caused CRPC progression via the downstream JAK2/STAT1 signal transduction cascade. Combined inhibition targeting both the AR and JAK2/STAT1 resulted in substantial tumor suppression due to the reduction in DNA damage repair ability and increment in apoptosis.
BibTeX
@inproceedings{luo2021enzalutamide,
  author = {Yong Luo and Xiaobing Yang and Spyridon P. Basourakos and Xuemei Zuo and Dechao Wei and Jiahui Zhao and Mingchuan Li and Qiankun Li and Tao Feng and Pengju Guo and Yongguang Jiang},
  title = {{Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway}},
  booktitle = {Frontiers in Molecular Biosciences},
  year = {2021},
  doi = {10.3389/fmolb.2021.652443},
}
Figure